Willars, Gary B., Werner Mü ller-Esterl, and Stefan R. Nahorski. Receptor phosphorylation does not mediate cross talk between muscarinic M 3 and bradykinin B 2 receptors. Am. J. Physiol. 277 (Cell Physiol. 46): C859-C869, 1999.-This study examined cross talk between phospholipase Ccoupled muscarinic M 3 and bradykinin B 2 receptors coexpressed in Chinese hamster ovary (CHO) cells. Agonists of either receptor enhanced phosphoinositide signaling (which rapidly desensitized) and caused protein kinase C (PKC)-independent, homologous receptor phosphorylation. Muscarinic M 3 but not bradykinin B 2 receptors were also phosphorylated after phorbol ester activation of PKC. Consistent with this, muscarinic M 3 receptors were phosphorylated in a PKC-dependent fashion after bradykinin B 2 receptor activation, but muscarinic M 3 receptor activation did not influence bradykinin B 2 receptor phosphorylation. Despite heterologous phosphorylation of muscarinic M 3 receptors, phosphoinositide and Ca 2ϩ signaling were unaffected. In contrast, marked heterologous desensitization of bradykinin-mediated responses occurred despite no receptor phosphorylation. This desensitization was associated with a sustained component of muscarinic receptor-mediated signaling, whereas bradykinin's inability to influence muscarinic receptor-mediated responses was associated with rapid and full desensitization of bradykinin responses. Thus the mechanism of functional cross talk most likely involves depletion of a shared signaling component. These data demonstrate that receptor phosphorylation is not a prerequisite for heterologous desensitization and that such desensitization is not obligatory after heterologous receptor phosphorylation. receptor desensitization; phospholipase C-coupled receptors
A GENERAL SCHEME FOR rapid desensitization of G proteincoupled receptors (GPCRs) has evolved, in which agonist occupation of a receptor results in phosphorylation of sites within the carboxy-terminal tail and/or third intracellular loop and this ultimately results in receptor/G protein uncoupling (14, 20, 26, 27) . Although much of this scheme has been established through work on the G s ␣-coupled ␤ 2 -adrenoceptor, there is accumulating evidence that a similar mechanism underlies the acute regulation of GPCRs coupled to other signal transduction pathways (11, 27) . In the case of the ␤ 2 -adrenoceptor, phosphorylation, particularly at high levels of receptor occupancy, is mediated via ␤-adrenergic receptor kinase (14, 20) . This kinase is a member of a family of kinases, known as the G protein-coupled receptor kinases (GRKs), which appear to have a broad substrate specificity (17) , including receptors coupled to the activation of phospholipase C (PLC) (11, 27) . The physiologically relevant kinases for PLC-coupled receptors remain, however, to be defined and indeed may include kinases distinct from those of the GRK family such as casein kinase 1␣ (30) . Receptor phosphorylation by such kinases is dependent on agonist occupation (20, 27) , which ensures that the negative regulation imparted by this covalent modification is strictly homologous.
Many GPCRs are also substrates for second-messenger-activated kinases, thereby providing an alternative mechanism for receptor phosphorylation and desensitization (14, 20, 27) . For a limited number of receptors, second-messenger-activated kinases such as protein kinase A (PKA) and PKC have been implicated in agonistmediated homologous receptor phosphorylation, particularly at low agonist concentrations (1-4, 6, 20, 25) . Whether this turns out to be a general phenomenon remains to be established, and the current perspective is that, for the great majority of receptors, agonist-mediated phosphorylation is predominantly or exclusively via a GRK or related kinase. The phosphorylation of receptors by secondmessenger-activated kinases can, however, also occur in the absence of agonist occupation (20, 27) . This potentially adds an additional dimension to receptor regulation in providing a mechanism for heterologous phosphorylation between different receptors coupled to the same or distinct signal transduction pathways. It is still unclear whether such interactions are widespread amongst GPCRs and whether this provides a common and indeed obligatory mechanism for heterologous desensitization, and, if not, what other factors may provide additional or alternative means of functional regulation in a heterologous manner.
We have previously reported that stimulation of PLC-coupled muscarinic receptors (predominantly M 3 ), endogenously expressed in SH-SY5Y human neuroblastoma cells, is able to markedly inhibit signaling by bradykinin B 2 receptors (34) . In contrast, stimulation of bradykinin receptors was unable to influence muscarinic receptor signaling. Although we provided evidence to suggest that the sustained depletion of a shared intracellular Ca 2ϩ pool may be required for desensitization of both Ca 2ϩ and phosphoinositide signaling (through lack of a Ca 2ϩ feed-forward facilitation of PLC), the current study was designed to examine the influence of heterologous receptor phosphorylation on the functional interaction between these two receptor types. To ensure significant receptor expression to allow determination of receptor phosphorylation, we have developed a Chinese hamster ovary (CHO) cell line that stably coexpresses recombinant human muscarinic M 3 and bradykinin B 2 receptors. Although our previous study in SH-SY5Y cells implied interaction between these two receptor types, these cells express at least multiple muscarinic receptor subtypes, which has the potential to cloud interpretation. The CHO cell line used in the current study therefore has the added advantage that any observed interactions are between single receptor subtypes.
MATERIALS AND METHODS

Materials
Reagents of analytical grade were obtained from suppliers listed previously (33, 37) 
Cell Culture
Cells were cultured in MEM ␣ medium supplemented with 50 IU/ml penicillin, 50 µg/ml streptomycin, and 10% (vol/vol) FCS. Cultures were maintained at 37°C in 5% CO 2 /humidified air and passaged weekly. For experiments, cells were harvested with 10 mM HEPES, 154 mM NaCl, 0.54 mM EDTA (pH 7.4), and, with the exception of experiments in which the intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) was measured (see Measurement of [Ca 2ϩ ] i ), were reseeded at an approximately equivalent density into 24-well multidishes for use 1-2 days later. Cells were maintained and the experimental manipulations performed at 37°C unless otherwise stated.
Transfection of CHO-M 3 Cells With cDNA Encoding Human Bradykinin B 2 Receptor
CHO cells that had previously been transfected with the human muscarinic M 3 receptor in pcDNA3 (Invitrogen, CA) containing the neomycin resistance gene (28) (CHO-M 3 cells) were transfected with cDNA encoding the human bradykinin B 2 receptor using a standard calcium phosphate method. The cDNA for the bradykinin B 2 receptor had been cloned (Not I/Xho I) into the pCEP4 plasmid containing the hygromycin resistance gene (Invitrogen). Cells were selected using hygromycin B (400 U/ml) and screened by assessing the ability of bradykinin to generate D-myo-inositol 1,4,5-trisphosphate [Ins (1, 4, 5 Cells were washed rapidly with two 1-ml volumes of ice-cold buffer and digested with 0.5 ml of 0.1 M NaOH. This was neutralized with 0.5 ml of 1 M TCA, and 3 H was determined by liquid scintillation spectroscopy in 5 ml of Floscint IV.
Bradykinin receptor density was determined by the binding of the bradykinin B 2 receptor antagonist [ 3 H]NPC 17731 5[prolyl-3,4-3 H(N)]-D-Arg-Arg-Pro(3,4-3 H)-Hyp-Gly-Phe-Ser-DHypEtrans-propyl-Oic-Arg: 53.5 Ci/mmol6 to intact cells. Cells in 24-well multiwells were washed and incubated for 90 min at 37°C in 1 ml of Krebs/HEPES buffer containing a range of concentrations of [ 3 H]NPC (ϳ0.15-50 nM). The buffer also contained 1 mM captopril to prevent degradation of the 20 µM bradykinin used to determine nonspecific binding. After incubation, cells were processed as described above.
Generation and Measurement of Ins(1,4,5)P 3
Media were removed from confluent cell monolayers in 24-well multidishes. Each well was washed with 1 ml Krebs/ HEPES buffer and preincubated for 10 min in a further 1 ml of buffer. This buffer was then removed and the cells challenged with 200 µl of buffer containing agonist. In experiments that required pretreatment with either agonist, phorbol ester, or PKC inhibitor, all agents were added in 100-µl aliquots. All reactions were performed in duplicate. Reactions were stopped with equivalent volumes of 1 M TCA, and a 160-µl aliquot of the acidified aqueous phase was removed, processed, and assayed for Ins(1,4,5)P 3 by a radioreceptor assay as previously described (10, 34, 35) . were then extracted and determined exactly as previously described (37) .
Measurement of Total PLC Activity
Measurement of [Ca 2ϩ ] i
Single cell imaging. Cells were harvested and reseeded onto round glass coverslips (no. 1, 22 mm diameter; Chance Propper, Warley, UK). Cells were allowed to attach overnight and were washed with Krebs/HEPES buffer and incubated in this buffer for 1 h at room temperature with fura 2-AM (2 µM). Coverslips were then mounted on the stage of a Nikon Diaphot inverted epifluorescence microscope. After excitation at 340 and 380 nm, fluorescent images at wavelengths Ͼ510 nm were collected with an intensified charge-coupled device camera (Photonic Science). The 340/380 nm ratio was calculated using the Applied Imaging ''Quanticell 700'' system. Population studies. Confluent monolayers of cells in 175-cm 2 flasks were harvested and resuspended in 2.5 ml of Krebs/HEPES buffer. A 0.5-ml aliquot of this was removed for determination of cellular autofluorescence. Fura 2-AM (5 µM) was added to the remaining 2 ml, which was then left for ϳ40 min at room temperature with gentle mixing. Supernatant containing extracellular fura 2-AM was then removed following gentle centrifugation of 0.5-ml aliquots. Cells were then resuspended in 3 ml of Krebs/HEPES buffer. With emission recorded at 509 nm, the 340/380 nm excitation ratio was recorded every 1 s as an index of [Ca 2ϩ ] i . Cells were challenged with 10-50 µl of agonist.
Both single-cell imaging and population [Ca 2ϩ ] i studies were performed at room temperature, as at 37°C there was a profound leak and/or extrusion of fura 2 into the extracellular buffer. Although this was overcome by the inclusion of probenecid (2.5 mM, data not shown), we have evidence that this alters sustained signaling by PLC-coupled receptors (N. R. Johnson and S. R. Nahorski, unpublished data), and we chose, therefore, to overcome the problem by carrying out the experiments at a lower temperature.
Receptor Phosphorylation
Assessment of muscarinic M 3 receptor phosphorylation in vivo was determined using a modification of a previously described protocol (29) . Briefly, cells in six-well multidishes were washed with Krebs/HEPES buffer without KH 2 PO 4 and incubated for 1 h at 37°C in 1 ml of buffer per well containing 50 µCi of [ 32 P]orthophosphate. Test agents were then added directly to the wells and incubation continued at 37°for the required time. When the PKC inhibitor Ro-31-8220 51-[3-(amidinothio)propyl-1H-indol-3-yl]-3-(1-methyl-1H-indol-3-yl)-maleimide, methane sulphonate6 was used, this was added 10 min before the test agent. After the required time, buffer was aspirated and 1 ml of ice-cold solubilization buffer added (10 mM Tris, 10 mM EDTA, 500 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 100 µg/ml iodoacetamide, and 100 µg/ml benzamidine, pH 7.4). After 30 min on ice, the solubilization buffer was removed and centrifuged (3 min at 10,000 g). The primary antibody was then added to 0.8 ml of the cleared supernatant. This antibody was raised in rabbit against a fusion protein representing a portion of the third intracellular loop of the human muscarinic M 3 receptor (Ser 345 -Leu 463 ) and has been previously described and characterized (designated antibody 332) (29) . After 60 min on ice, immune complexes were separated by incubation with protein ASepharose beads (150 µl of 30 mg/ml) at 4°C under constant agitation. Beads were harvested by centrifugation (10 s at 13,000 g) and washed three times with 1 ml of ice-cold TE buffer (10 mM Tris, 10 mM EDTA, pH 7.4). Samples were extracted into 20 µl of sample buffer (100 mM Tris · HCl, 2% SDS, 10% glycerol, 0.1% bromophenol blue, and 200 mM dithiothreitol) by standing in water at 70°C for 5 min. Proteins were then resolved by 8% SDS-PAGE. The gels were dried and subjected to autoradiography for 1-3 days.
Bradykinin B 2 receptor phosphorylation was determined in an identical fashion, with the exception that the cleared supernatant was preadsorbed (15-30 min, 4°C) with protein A-Sepharose beads (100 µl of 30 mg/ml), and 0.8 ml of the resulting supernatant was used for immune precipitation with the bradykinin B 2 receptor antibody. In addition, the protein A-Sepharose immune complex was washed twice with 1 ml of ice-cold 100 mM Tris base, 1.5 M NaCl, 0.5% Tween-20 (pH 7.4) before the final washes with TE buffer. The bradykinin B 2 receptor antibody was raised against a region of the carboxy-terminal tail of the human receptor (Cys 361 -Gln 395 ) and has been previously described and characterized [designated antiserum anti-ID4 (AS346)] (8).
Where required, densitometric analysis of autoradiographs was performed using a Bio-Rad GS-670 imaging densitometer with Molecular Analyst v1.2 software. Local background subtraction was applied to images and data normalized to basal (nonstimulated) receptor phosphorylation.
Data Presentation
For quantitative determinations of [ 3 H]InsP x and Ins(1,4,5)P 3 , cell incubations were carried out in duplicate. These duplicate values were averaged to give a single value representative of one experiment. All data are presented as means Ϯ SE with the number of experiments (n) given in parentheses. Concentration-response curves and radioligand binding curves were fitted by GraphPad Prism (GraphPad Software, San Diego, CA) using a standard four-parameter logistic equation with equal weighting to all points. 
RESULTS
Transfection
Agonist-Mediated Changes in Ins(1,4,5)P 3
A challenge of cells with the muscarinic agonist methacholine (1 mM) resulted in a rapid elevation of Ins(1,4,5)P 3 to a peak of approximately sevenfold over basal within 5-10 s of agonist addition. In the continued presence of agonist, levels returned to approximately threefold over basal over the subsequent minute, and this was sustained throughout the remainder of the experiment (Fig. 1A) . A challenge of cells with bradykinin (10 µM) also resulted in a rapid elevation of Ins(1,4,5)P 3 to ϳ3.5-fold over basal at 5-10 s. Ins(1,4,5)P 3 then fell over the subsequent minute to within 20% of basal levels and had returned to basal levels by 15 min (Fig. 1B) . Figure 1C demonstrates the marked contrast between sustained Ins(1,4,5)P 3 signaling mediated by muscarinic M 3 receptor activation and the transient response mediated by activation of bradykinin B 2 receptors. A number of other clones were examined, which displayed lower peak Ins(1,4,5)P 3 responses to bradykinin but still displayed no evidence of a sustained response (data not shown). The inability of bradykinin to elicit a sustained Ins(1,4,5)P 3 response was not a consequence of the metabolism of bradykinin by cell surface degradative enzymes, as further addition of bradykinin failed to elevate Ins(1,4,5)P 3 levels (data not shown). Furthermore, the angiotensinconverting enzyme inhibitor captopril (1 mM) did not influence the magnitude or temporal profile of bradykinin-mediated Ins(1,4,5)P 3 elevation (data not shown). Other clones also accumulated Ins(1,4,5)P 3 in response to either bradykinin or methacholine, with temporal profiles identical to those shown here, although the The peak elevations of Ins(1,4,5)P 3 in response to either methacholine or bradykinin were concentration dependent, with EC 50 values (log 10 M) of Ϫ6.20 Ϯ 0.16 (n ϭ 6; 0.63 µM) and Ϫ7.59 Ϯ 0.04 (n ϭ 6; 26 nM), respectively.
Agonist-Mediated Changes in [ 3 H]InsP x
In [ 3 H]inositol-labeled cells, in which inositol monophosphatase activity had been blocked with Li ϩ , methacholine produced an accumulation of [ 3 H]InsP x that was 86% over basal after 1 min. Over the subsequent 9 min of stimulation, methacholine evoked [ 3 H]InsP x accumulation at 37%/min, which represents an approximately twofold lower rate of accumulation than over the first minute of agonist challenge. Bradykinin (10 µM) evoked an accumulation of [ 3 H]InsP x , which was 32% over basal levels after 1 min. Between 1 and 10 min of stimulation, bradykinin evoked [ 3 H]InsP x accumulation at a rate of 5.8%/min, which is more than fivefold lower than that over the first minute (Fig. 2 ). These data demonstrate a relative lack of sustained PLC activation during challenge with bradykinin.
Agonist-Mediated Changes in [Ca 2ϩ ] i
Single-cell imaging of fura 2-loaded cells indicated that the majority of cells (Ͼ80%) responded with an increase in [Ca 2ϩ ] i following challenge with either 1 mM methacholine or 1 µM bradykinin (data not shown). In populations of cells, 1 mM methacholine resulted in a rapid elevation of [Ca 2ϩ ] i from basal (0.85 Ϯ 0.03; n ϭ 3; all values are given as the 340/380 ratio) to a transient peak (3.50 Ϯ 0.24; n ϭ 3; Fig. 3 ), which is equivalent to a change in [Ca 2ϩ ] i in these cells of ϳ100 to 750 nM (data not shown). The [Ca 2ϩ ] i then fell quickly to a level (1.29 Ϯ 0.06; n ϭ 3) that was in excess of basal levels and subsequently rose gradually. The (Fig. 3) .
Homologous Receptor Phosphorylation
Using the muscarinic M 3 receptor antibody we show that a methacholine (1 mM, 5 min) challenge of CHO cells expressing the muscarinic M 3 receptor either alone (CHO-M 3 ) or in combination with the bradykinin B 2 receptor (CHO-M 3 /B 2 ) resulted in a marked increase in the amount of [ 32 P]orthophosphate associated with a band of ϳ100 kDa (Figs. 4 and 5) . This band was not observed in CHO cells expressing only the bradykinin B 2 receptor (CHO-B 2 ) or only the muscarinic M 1 receptor (CHO-M 1 ), even when the PLC pathway was activated through challenge of the cells with the appropriate agonist (bradykinin or methacholine, respectively; Fig. 4 ). In cells expressing the muscarinic M 3 receptor, changes in phosphorylation were sometimes observed toward the top of the gel, but it is unclear whether this represents receptor aggregates/dimers formed physiologically or during the preparative process. The increase in phosphorylation of the muscarinic M 3 receptor was blocked by the muscarinic receptor antagonist atropine (Fig. 5B ) but was relatively unaffected by preincubation of the cells with the PKC inhibitor Ro-31-8220 (Fig. 5A) . The phorbol ester phorbol 12,13-dibutyrate (PDBu) increased the level of phosphorylation of the muscarinic M 3 receptor in line with the level observed following agonist treatment. Phorbol estermediated phosphorylation was fully blocked by inhibition of PKC with Ro-31-8220 (Fig. 5A) . The current data are consistent with our previous observation of a rapid, PKC-independent phosphorylation of a band representing the muscarinic M 3 receptor at 100 kDa in CHO cells, which is maximal within 1 min and sustained for at least 30 min (29) .
Using the bradykinin B 2 receptor antibody we show that in CHO-B 2 or CHO-M 3 /B 2 cells, challenge with bradykinin resulted in an increase in the level of phosphorylation of two diffuse bands of ϳ60 and 70-90 kDa (Figs. 4 and 6) . No bands were observed in CHO-M 3 or CHO-M 1 cells, even when the PLC pathway was activated through challenge of the cells with methacholine (Fig. 4) . The apparent molecular masses of the two bands representing the bradykinin B 2 receptor are slightly greater than that observed for the receptor expressed endogenously in HF-15 human fibroblasts in which bands were observed at 69 and 52 kDa (8) . Such differences in apparent molecular mass may result from differential processing of the receptor as a consequence either of expression in different cell lines or expression as a recombinant vs. endogenously expressed protein. It is probable that the two bands of differing molecular mass represent two forms of the receptor, but we have no evidence to suggest that the higher molecular mass form is a receptor dimer. Although the predicted molecular mass of the bradykinin B 2 receptor is 41 kDa, GPCRs rarely run at their predicted size due to posttranslational modifications. Indeed, in human foreskin fibroblasts, experimental deglycosylation of the bradykinin B 2 receptor shifts its apparent molecular mass from 69 to 44 kDa (5) . Furthermore, in these cells the major ligand-binding form of the receptor was the 69-kDa band (5) . Analysis of changes in the phosphorylation status of the bradykinin B 2 receptor have been performed on the higher molecular weight band, although in all instances changes occurred in both bands and paralleled each other.
Challenge of the CHO-M 3 /B 2 cells for 5 min with 10 µM bradykinin increased the level of phosphorylation of the bradykinin B 2 receptor in a manner unaffected by inhibition of PKC with Ro-31-8220 (Fig. 6A ) but which was blocked by the bradykinin B 2 receptor antagonist HOE-140 (Fig. 6B) . Incubation of cells with PDBu or both PDBu and Ro-31-8220 did not result in significant changes in the phosphorylation level of the bradykinin B 2 receptor (Fig. 6A) . These data are consistent with the homologous, rapid, PKC-independent phosphorylation of the bradykinin B 2 receptor in HF-15 cells (8) .
Heterologous Receptor Phosphorylation
Challenge of cells with 10 µM bradykinin resulted in an increase in the level of muscarinic M 3 receptor phosphorylation, which was prevented by the PKC inhibitor Ro-31-8220 (Fig. 7A) or the bradykinin B 2 receptor antagonist HOE-140 (Fig. 7B ). This heterologous phosphorylation was rapid and maximal at ϳ5 min (Fig. 7C) . Challenge of cells with 1 mM methacholine for 5 min did not result in phosphorylation of the bradykinin B 2 receptor (Fig. 8) .
Sensitivity of Muscarinic M 3 -or Bradykinin B 2 -Receptor-Mediated Signaling to PKC Activation
Pretreatment of cells with 1 µM PDBu for 5 min before agonist challenge resulted in a significant (P ϭ 0.016, t-test) reduction in the potency of methacholinemediated peak Ins(1,4,5)P 3 responses with EC 50 values (log 10 M) of Ϫ5.88 Ϯ 0.09 (n ϭ 4) and Ϫ5.41 Ϯ 0.12 (n ϭ 4) in the absence and presence of PDBu, respectively. PDBu did not, however, affect the magnitude of the response mediated by a maximal concentration of methacholine (Fig. 9A) . In contrast, PDBu reduced the magnitude of the Ins(1,4,5)P 3 responses to bradykinin (P ϭ 0.0001, two-way ANOVA). However, this was a result of a PDBu-mediated reduction in the basal level of Ins(1,4,5)P 3 , and the proportional bradykininmediated increases in Ins(1,4,5)P 3 were similar in the presence and absence of PDBu. The potency of bradykinin was unaffected with EC 50 values (log 10 M) of Ϫ7.28 Ϯ 0.12 (n ϭ 4) and Ϫ7.21 Ϯ 0.16 (n ϭ 4) in the absence and presence of PDBu, respectively (Fig. 9B) .
Functional Interactions Between Muscarinic M 3 Receptor and Bradykinin B 2 Receptor Signaling
Pretreatment of cells with either bradykinin (10 µM, 5 min), Ro-31-8220 (10 µM, 10 min), or the two in combination had no significant effect on the potency or magnitude of methacholine-mediated Ins(1,4,5)P 3 responses (Fig. 10) .
Pretreatment of cells for 5 min with 1 mM methacholine elevated Ins(1,4,5)P 3 from a basal level of 86 Ϯ 6 (n ϭ 4) to 254 Ϯ 11 pmol/mg protein (n ϭ 4). Subsequent addition of bradykinin resulted in a minor elevation of Ins(1,4,5)P 3 (20 Ϯ 10 pmol/mg protein; n ϭ 4), which was only 22 Ϯ 9% (n ϭ 4; P Ͻ 0.01) of the response in the absence of pretreatment with methacholine (84 Ϯ http://ajpcell.physiology.org/ 16.9 pmol/mg protein; n ϭ 4). In additional experiments, a 10-min preincubation of cells with 10 µM Ro-31-8220 did not restore the ability of 10 µM bradykinin to elevate Ins(1,4,5)P 3 5 min after and in the continued presence of 1 mM methacholine (320 Ϯ 51 pmol/mg protein, n ϭ 4, vs. 295 Ϯ 42 pmol/mg protein, n ϭ 4, in the absence and presence of Ro-31-8220, respectively).
The addition of 10 µM bradykinin 5 min after (and in the continued presence of) 1 mM methacholine failed to produce an elevation of [Ca 2ϩ ] i (Fig. 11A) . In contrast, the addition of 1 mM methacholine 5 min after (and in the continued presence of) 10 µM bradykinin resulted in a marked elevation of [Ca 2ϩ ] i . The peak elevation of [Ca 2ϩ ] i in response to methacholine (340/380 ratio: 1.54 Ϯ 0.14; n ϭ 3) was reduced compared with that in the absence of bradykinin (340/380 ratio: 2.65 Ϯ 0.19; n ϭ 3; P ϭ 0.0495 Mann-Whitney U test; Fig. 11B ). When the methacholine concentration was lowered (to 0.3 µM) to reduce the [Ca 2ϩ ] i response, challenge with bradykinin still failed to evoke an elevation of [Ca 2ϩ ] i (Fig. 11C) . In contrast, this lower concentration of methacholine was still able to evoke an elevation of [Ca 2ϩ ] i following and in the continued presence of bradykinin, which was not significantly different from that in the absence of bradykinin (0.55 Ϯ 0.07, n ϭ 3, vs. 0.75 Ϯ 0.08, n ϭ 3, in the presence and absence of bradykinin respectively, P ϭ 0.1266 Mann-Whitney U test; Fig. 11D ).
DISCUSSION
This study demonstrates a functional interaction between two PLC-coupled GPCRs coexpressed on the same CHO cell. Despite homologous phosphorylation of both bradykinin B 2 and muscarinic M 3 receptors in these cells, using the current methodology we have only been able to demonstrate heterologous phosphorylation of the latter. Surprisingly, this PKC-dependent heterologous phosphorylation was not associated with functional desensitization. Furthermore, activation of muscarinic M 3 receptors markedly inhibited bradykinin-mediated Heterologous phosphorylation of muscarinic M 3 receptors but not bradykinin B 2 receptors occurred, despite greater phosphoinositide and Ca 2ϩ responses following muscarinic receptor activation, thereby implying receptor specificity. Although the extent of heterologous phosphorylation was comparatively low (1.5-to 2.5-fold over basal), this is consistent with the heterologous phosphorylation of other PLC-coupled receptors (16, 21, 31) . The current data also parallel that describing a degree of heterologous phosphorylation considerably less than either homologous phosphorylation or that following activation of PKC by phorbol ester (3, 16) . It remains to be established whether this is related to the activation of different kinases or phosphorylation of different sites. The pattern of heterologous phosphorylation correlates with the observation that there is a substantial phosphorylation of muscarinic M 3 receptors but not bradykinin B 2 receptors following activation of PKC with phorbol ester. This may be a consequence of the 16 intracellular PKC consensus sites of the muscarinic M 3 receptor compared with only 4 of the bradykinin B 2 receptor, of which only 2 (Thr 264 and Thr 369 ) are on the cytosolic side of the plasma membrane. It is possible, therefore, that the effect of PDBu on the potency of muscarinic receptor-mediated elevations of Ins(1,4,5)P 3 and not those in response to bradykinin are a reflection of these differences in PKC-mediated receptor phosphorylation, although it is clear that activated PKC can also inhibit signaling at a postreceptor level (7, 24, 33) .
We have previously demonstrated a similar unidirectional functional interaction between endogenously expressed muscarinic and bradykinin receptors of SH-SY5Y human neuroblastoma cells (34) . Although these cells express predominantly muscarinic receptors of the M 3 subtype, they also express other subtypes (32), and we also cannot discount the possibility of multiple bradykinin receptor subtypes. The present study not only demonstrates that cross talk is not dependent on the coexpression of multiple receptor subtypes but that the greater level of receptor expression has enabled us to examine receptor phosphorylation. In the current study we sought to match (or at least maximize) the bradykinin receptor-mediated signaling with that of the muscarinic receptor-mediated signaling (rather than matching levels of receptor expression). This has resulted in the use of a cell line expressing much greater levels of muscarinic M 3 receptors than bradykinin B 2 receptors. However, despite this, the phosphoinositide and Ca 2ϩ signaling data (specifically the patterns of homologous and heterologous desensitization) are entirely in accord with that seen in SH-SY5Y cells (34) that express approximately equivalent (and much lower) amounts (ϳ300 fmol/mg membrane protein) of these receptors (A. K. Martin, S. R. Nahorski, and G. B. Willars, unpublished data). In addition, in the current study, methacholine-mediated Ins(1,4,5)P 3 responses were unaffected over the concentration-response curve following maximal activation of bradykinin receptors. This demonstrates that the unidirectional nature of the heterologous desensitization was not due to different levels of receptor-effector coupling.
Our previous study in SH-SY5Y cells showed that the ability of muscarinic receptors to inhibit bradykinin receptor-mediated Ca 2ϩ signaling is dependent on their persistent activation (34) . Furthermore, recovery of the bradykinin response following removal of muscarinic receptor stimulation required extracellular Ca 2ϩ and was complete at a time (2-3 min) consistent with the time required to refill intracellular Ca 2ϩ stores in these cells (34) . These data support a model in which the depletion of a shared intracellular Ca 2ϩ store by muscarinic receptor stimulation results in the heterologous desensitization of [Ca 2ϩ ] i responses to bradykinin in SH-SY5Y cells and is entirely consistent with results in the current study. From this hypothesis, we would predict that the cross talk between these receptors would be dictated by the profiles of homologous desensitization. Using the accumulation of total inositol phosphates against a Li ϩ block (7, 13, 22, 35, 38) , we show that muscarinic M 3 receptors and bradykinin B 2 receptors do indeed display different patterns of homologous desensitization. In agreement with results examining these receptors endogenously expressed in SH-SY5Y cells (34, 35) , bradykinin B 2 receptors undergo rapid and full desensitization, whereas muscarinic M 3 receptors have a sustained component of signaling. The reasons for these differences are unclear, although, consistent with a role for phosphorylation in desensitization (8, 29) , both receptor types were subject to agonist-dependent phosphorylation in a PKC-independent manner. The consequence of these different patterns of homologous desensitization is that, in the continued presence of methacholine, intracellular Ca 2ϩ stores will remain depleted and be unavailable for release on the addition of bradykinin. In contrast, the full desensitization of bradykinin B 2 receptors will result in refilling of the Ca 2ϩ stores, thereby allowing responses via the coexpressed muscarinic M 3 receptors. The ability of bradykinin to slightly reduce the [Ca 2ϩ ] i response to a maximal but not submaximal concentration of methacholine is most likely due to the incomplete refilling of the Ca 2ϩ stores as the response to bradykinin declined.
In addition to the depletion of a shared intracellular Ca 2ϩ store, we have previously demonstrated that activation of muscarinic receptors expressed in either SH-SY5Y cells or CHO cells also results in rapid, marked, and sustained depletion of phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P 2 ], which recovers over several minutes following termination of receptor activation (15, 37) . Depletion of a shared substrate pool has the potential, therefore, to contribute to heterologous desensitization of bradykinin receptor-mediated responses shown here and in SH-SY5Y cells (34) . However, recovery of bradykinin-mediated Ins(1,4,5)P 3 responses following termination of muscarinic receptor activation is dependent on extracellular Ca 2ϩ (34) , whereas recovery of PtdIns(4,5)P 2 is not (36) . This provides evidence that depletion of a shared intracellular Ca 2ϩ store by methacholine underlies inhibition of bradykinin-mediated responses and supports the idea that heterologous desensitization of Ins(1,4,5)P 3 responses may occur due to lack of Ca 2ϩ feed-forward activation or facilitation of PLC (34, 38) . It is also possible that the muscarinic M 3 receptor is able to couple to intracellular effector molecules that the brady- http://ajpcell.physiology.org/ kinin B 2 receptor is unable to influence, thereby providing the basis for such unidirectional interaction. We are at present unable to address this issue.
The current data do not discount a role for phosphorylation in heterologous desensitization of phosphoinositide signaling in other circumstances. Indeed this has been suggested elsewhere (3, 16, 19, 31) , although a recent study also failed to demonstrate a functional consequence of bradykinin on signaling by the PLCcoupled ␣ 1B -adrenoceptor, despite heterologous receptor phosphorylation (21) . It is unclear whether differences are receptor or cell specific. Even in instances where receptors are substrates for PKC, a functional effect may depend on the presence of appropriate PKC isoforms and on their activation being of sufficient magnitude and duration. These latter features may in themselves be dependent on the temporal profile of homologous desensitization and the efficacy of coupling of the activated GPCR responsible for the heterologous phosphorylation.
It is possible that heterologous receptor phosphorylation regulates the nature of signaling in ways not explored here, thereby shaping cellular responses. For example, phosphorylation of ␤ 2 -adrenoceptors by PKA switches their coupling from G s ␣ to G i ␣ (12), whereas PKCdependent phosphorylation of 5-hydroxytryptamine 1A receptors results in uncoupling from Ca 2ϩ mobilization but not from inhibition of cAMP (18) . The current study does, however, show that heterologous receptor phosphorylation is not obligatory for heterologous desensitization of phosphoinositide and Ca 2ϩ signaling. Certainly in some circumstances postreceptor mechanisms, such as Ca 2ϩ store depletion, will represent the major factor underlying such cross talk. Indeed, this type of desensitization is an inevitable consequence of receptors sharing a common component of the signaling pathway, which has the potential to be rate limiting, and the duration of desensitization will be determined by the resupply of this component. Receptor phosphorylation may, in some circumstances, provide an additional mechanism for heterologous interaction and allow for a functional desensitization that outlives the depletion of signaling components such as the intracellular Ca 2ϩ store.
